Summary
Thermo Fisher Scientific Inc. reported solid revenue growth in the third quarter and first nine months of 2022, driven by strong performance in North America and Asia Pacific, and across its Laboratory Products and Biopharma Services and Analytical Instruments segments. However, overall revenue growth was tempered by a significant decline in COVID-19 testing demand, particularly impacting the Life Sciences Solutions and Specialty Diagnostics segments. Despite the revenue headwinds and increased strategic investments, the company demonstrated resilience through effective pricing strategies and productivity improvements, though operating margins saw a decrease compared to the prior year. The company continues to focus on its three-pillar growth strategy: innovation, leveraging scale in emerging markets, and delivering unique customer value. A notable strategic move during the period was the agreement to acquire The Binding Site Group for £2.25 billion, which is expected to enhance its Specialty Diagnostics segment. The company also managed its capital effectively, with substantial cash flow from operations and a focus on strategic acquisitions, share buybacks, and dividends, while maintaining a strong liquidity position.
Key Highlights
- 1Total revenues increased by 14% to $10.68 billion for the third quarter and 17% to $33.47 billion for the first nine months of 2022, compared to the prior year periods.
- 2Organic revenue growth was impacted by a significant decrease in COVID-19 related product sales, with sales declining from $1.57 billion in Q3 2021 to $0.44 billion in Q3 2022, and from $5.44 billion in the first nine months of 2021 to $2.75 billion in the same period of 2022.
- 3The Laboratory Products and Biopharma Services segment showed strong growth, with revenues up 60% in Q3 and 55% in the first nine months, largely driven by the acquisition of PPD and strong performance in pharma services.
- 4Operating income decreased by 25% in Q3 and 13% in the first nine months, with operating margins also declining due to lower COVID-19 volumes, strategic investments, and acquisition integration costs.
- 5The company has agreed to acquire The Binding Site Group for £2.25 billion to strengthen its Specialty Diagnostics segment.
- 6Free cash flow remained robust, though decreased to $3.99 billion for the first nine months of 2022 from $5.17 billion in the prior year period, reflecting investments in working capital and acquisitions.
- 7The company maintained a strong liquidity position with $2.92 billion in cash and cash equivalents and an undrawn $5 billion revolving credit facility as of October 1, 2022.